We are extremely disappointed that talks to reach a price agreement that would have made advanced breast cancer drug Enhertu available to around 1000 women in England and Wales have not been ...

Crovalimab is recommended, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more. It is recommended for ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

There is a commercial arrangement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] for ...

There is a simple discount patient access scheme for crovalimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Crovalimab (Piasky) is available on the NHS. It is a possible treatment for paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more and: have haemolysis with clinical ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Pembrolizumab (Keytruda, Merck Sharp and Dohme) 'in combination with platinum-containing chemotherapy, as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated ...